3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Leukemia, Myeloid, Acute
20
Lymphoma, Non-Hodgkin
19
Hodgkin Disease
18
Multiple Myeloma
17
Myelodysplastic Syndromes
16
Lymphoma
16
Graft vs Host Disease
16
Lymphoma, Mantle-Cell
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Leukemia
14
Sarcoma
11
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, Follicular
11
Glioblastoma
11
Tuberous Sclerosis
10
Lymphoma, B-Cell, Marginal Zone
10
Carcinoma, Renal Cell
10
Neoplasms
9
Hematologic Neoplasms
9
Gliosarcoma
9
Carcinoma, Hepatocellular
9
Breast Neoplasms
9
Brain Neoplasms
9
Waldenstrom Macroglobulinemia
8
Myeloproliferative Disorders
8
Melanoma
8
Burkitt Lymphoma
8
Recurrence
7
Neoplasm Metastasis
7
Interventions
cemiplimab
2
Sirolimus
1
Prednisone
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cutaneous Squamous Cell Carcinoma
×
Sirolimus
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts